Identification of metabolites, clinical chemistry markers and transcripts associated with hepatotoxicity.
Early and accurate pre-clinical and clinical biomarkers of hepatotoxicity facilitate the drug development process and the safety monitoring in clinical studies. We selected eight known model compounds to be administered to male Wistar rats to identify biomarkers of drug induced liver injury (DILI) using transcriptomics, metabolite profiling (metabolomics) and conventional endpoints. We specifically explored early biomarkers in serum and liver tissue associated with histopathologically evident acute hepatotoxicity. A tailored data analysis strategy was implemented to better differentiate animals with no treatment-related findings in the liver from animals showing evident hepatotoxicity as assessed by histopathological analysis. From the large number of assessed parameters, our data analysis strategy allowed us to identify five metabolites in serum and five in liver tissue, 58 transcripts in liver tissue and seven clinical chemistry markers in serum that were significantly associated with acute hepatotoxicity. The identified markers comprised metabolites such as taurocholic acid and putrescine (measured as sum parameter together with agmatine), classical clinical chemistry markers like AST (aspartate aminotransferase), ALT (alanine aminotransferase), and bilirubin, as well as gene transcripts like Igfbp1 (insulin-like growth factor-binding protein 1) and Egr1 (early growth response protein 1). The response pattern of the identified biomarkers was concordant across all types of parameters and sample matrices. Our results suggest that a combination of several of these biomarkers could significantly improve the robustness and accuracy of an early diagnosis of hepatotoxicity.
F. Hoffmann-La Roche, Basel, Switzerland.
Andreas
A
Buness
F. Hoffmann-La Roche, Basel, Switzerland.
Adrian
A
Roth
F. Hoffmann-La Roche, Basel, Switzerland.
Annika
A
Herrmann
Metanomics GmbH, Berlin, Germany.
Oliver
O
Schmitz
BASF SE, Ludwigshafen, Germany.
Hennicke
H
Kamp
Metanomics Health GmbH, Berlin, Germany.
Kristina
K
Busch
F. Hoffmann-La Roche, Basel, Switzerland.
Laura
L
Suter
D000818:Animals; D015415:Biomarkers / Q000097:blood / Q000378:metabolism*; D001798:Blood Proteins / Q000378:metabolism; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology; D020869:Gene Expression Profiling / Q000379:methods; D008099:Liver / Q000378:metabolism* / Q000473:pathology; D008297:Male; D055432:Metabolomics / Q000379:methods; D051381:Rats; D017208:Rats, Wistar
D015415:Biomarkers; D001798:Blood Proteins